Translational studies: Drug candidates and preclinical testing

Nai Ki MAK; Hong Lok LUNG; K. F. Hui; A. K.S. Chiang; Fei Fei Liu

doi:10.1016/B978-0-12-814936-2.00006-7

Translational studies: Drug candidates and preclinical testing

Nai Ki MAK, Hong Lok LUNG, K. F. Hui, A. K.S. Chiang, Fei Fei Liu

Department of Biology

Research output: Chapter in book/report/conference proceeding › Chapter › peer-review

1 Citation (Scopus)

Abstract

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr-associated malignancy. Both the host and viral factors are known to contribute to the oncogenic development of NPC. NPC has a wide mutational diversity and many signaling pathways are known to be activated in the tumor cells. However, molecularly targeted therapeutic agents licensed for the treatment of NPC are still not available. This review will focus on several major areas related to the development of potential molecularly targeted drug candidates for the future treatment of NPC. These include the genetics-guided drug development and the therapeutic targeting of the viral factors in the tumors.

Original language	English
Title of host publication	Nasopharyngeal Carcinoma
Subtitle of host publication	From Etiology to Clinical Practice
Editors	Anne Lee, Maria Lung, Wai Ng
Publisher	Elsevier
Chapter	6
Pages	109-127
Number of pages	19
ISBN (Electronic)	9780128149379
ISBN (Print)	9780128149362
DOIs	https://doi.org/10.1016/B978-0-12-814936-2.00006-7
Publication status	Published - 23 Mar 2019

Scopus Subject Areas

Economics, Econometrics and Finance(all)
Business, Management and Accounting(all)

User-Defined Keywords

Epstein-Barr virus
Genetics-guided drugs
Nasopharyngeal carcinoma
Signaling pathways
Therapeutic target
Virus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-814936-2.00006-7

Cite this

@inbook{333940de4872475e9b16b45cc84f08d0,

title = "Translational studies: Drug candidates and preclinical testing",

abstract = "Nasopharyngeal carcinoma (NPC) is an Epstein-Barr-associated malignancy. Both the host and viral factors are known to contribute to the oncogenic development of NPC. NPC has a wide mutational diversity and many signaling pathways are known to be activated in the tumor cells. However, molecularly targeted therapeutic agents licensed for the treatment of NPC are still not available. This review will focus on several major areas related to the development of potential molecularly targeted drug candidates for the future treatment of NPC. These include the genetics-guided drug development and the therapeutic targeting of the viral factors in the tumors.",

keywords = "Epstein-Barr virus, Genetics-guided drugs, Nasopharyngeal carcinoma, Signaling pathways, Therapeutic target, Virus",

author = "MAK, {Nai Ki} and LUNG, {Hong Lok} and Hui, {K. F.} and Chiang, {A. K.S.} and Liu, {Fei Fei}",

year = "2019",

month = mar,

day = "23",

doi = "10.1016/B978-0-12-814936-2.00006-7",

language = "English",

isbn = "9780128149362",

pages = "109--127",

editor = "Anne Lee and Maria Lung and Wai Ng",

booktitle = "Nasopharyngeal Carcinoma",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Translational studies

T2 - Drug candidates and preclinical testing

AU - MAK, Nai Ki

AU - LUNG, Hong Lok

AU - Hui, K. F.

AU - Chiang, A. K.S.

AU - Liu, Fei Fei

PY - 2019/3/23

Y1 - 2019/3/23

N2 - Nasopharyngeal carcinoma (NPC) is an Epstein-Barr-associated malignancy. Both the host and viral factors are known to contribute to the oncogenic development of NPC. NPC has a wide mutational diversity and many signaling pathways are known to be activated in the tumor cells. However, molecularly targeted therapeutic agents licensed for the treatment of NPC are still not available. This review will focus on several major areas related to the development of potential molecularly targeted drug candidates for the future treatment of NPC. These include the genetics-guided drug development and the therapeutic targeting of the viral factors in the tumors.

AB - Nasopharyngeal carcinoma (NPC) is an Epstein-Barr-associated malignancy. Both the host and viral factors are known to contribute to the oncogenic development of NPC. NPC has a wide mutational diversity and many signaling pathways are known to be activated in the tumor cells. However, molecularly targeted therapeutic agents licensed for the treatment of NPC are still not available. This review will focus on several major areas related to the development of potential molecularly targeted drug candidates for the future treatment of NPC. These include the genetics-guided drug development and the therapeutic targeting of the viral factors in the tumors.

KW - Epstein-Barr virus

KW - Genetics-guided drugs

KW - Nasopharyngeal carcinoma

KW - Signaling pathways

KW - Therapeutic target

KW - Virus

UR - https://doi.org/10.1016/C2017-0-02349-2

UR - http://www.scopus.com/inward/record.url?scp=85075725833&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-814936-2.00006-7

DO - 10.1016/B978-0-12-814936-2.00006-7

M3 - Chapter

AN - SCOPUS:85075725833

SN - 9780128149362

SP - 109

EP - 127

BT - Nasopharyngeal Carcinoma

A2 - Lee, Anne

A2 - Lung, Maria

A2 - Ng, Wai

PB - Elsevier

ER -

Translational studies: Drug candidates and preclinical testing

Abstract

Scopus Subject Areas

User-Defined Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this